Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality

Phase

Safety & dosing

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

Sichuan Cancer Hospital and Research Institute, Shanxi Province Cancer Hospital

Enrollment target

~136 participants

Started

October 2023

Primary completion

October 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

70 Years – 90 Years

Last updated December 2023